Yüklüyor......
Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) gefitinib has demonstrated dramatic clinical efficacy in non-small cell lung cancer (NSCLC) patients. However, its therapeutic efficacy is ultimately limited by the development of acquired drug resistance. The aim of this study...
Kaydedildi:
| Yayımlandı: | Toxicol Appl Pharmacol |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5643250/ https://ncbi.nlm.nih.gov/pubmed/28942004 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.taap.2017.09.017 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|